What is most rewarding?
With a focus on the business side of diagnostics I get most excited about the outcomes. Our tests are covered by many health plans, giving patients access to answers while avoiding surgeries. That means that patients, as a result of our work, have a clear path forward. We are making a real difference.
Real People,
Real Science,
Real Answers.
President and Chief Operating Officer
This is the Age of Evidence.
Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek.

Veracyte gives patients a clearer path for the future.

We are leading in the Age of Evidence.
our impact
The Age
of Evidence
Veracyte's genomic tests have the potential to save billions of dollars each year in unnecessary surgery costs.
Learn More >
New data published in The Lancet Respiratory Medicine show that the Envisia Genomic Classifier improves diagnosis of IPF
learn more >
Bonnie Anderson, Veracyte CEO interview with Bill Vick/PF Warriors about the Envisia Genomic Classifier and plans to transform IPF/ILD diagnosis


latest news